Pfetin as a Prognostic Biomarker for Gastrointestinal Stromal Tumor: Validation Study in Multiple Clinical Facilities

Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems

(2011) Jian-Hong Zhong et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors

(2010) Jean-Yves Blay et al.   CANCER

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Pfetin as a Prognostic Biomarker in Gastrointestinal Stromal Tumor: Novel Monoclonal Antibody and External Validation Study in Multiple Clinical Facilities

(2009) K. Kikuta et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics

(2008) Y. Suehara et al.   CLINICAL CANCER RESEARCH